Lille (France), April 8th, 2021 – Alzprotect, a biopharmaceutical company developing therapeutic solutions for neurodegenerative diseases announces today today hat it has established its US based subsidiary, Alzprotect US Inc. in Boston, Massachusetts, in line with its international development strategy.

This new subsidiary of Alzprotect is situated in Boston. The world’s ten largest biopharma companies have a presence in Massachusetts, making it an ideal location for scientific and technological innovation and ideally suited for Alzprotect’ first US foothold.

The creation of this affiliate is the first milestone in a process that will lead to the initiation of Alzprotect’ clinical trials for the treatment of PSP and Alzheimer’s disease in the US.

Dr Philippe Verwaerde, CEO of Alzprotect, commented: “The creation of a subsidiary in the US is an important step forward in our strategy as set out in our future development. This further strengthens the international reach of our innovative pipeline for the treatment of neurodegeneration. We are very excited to become part of the biotechnology cluster in Cambridge and believe this prime location will prove to be extremely beneficial to the Company as we move our clinical development forward in this important market.”

Lille (France), March 7th, 2021 – Alzprotect, a biopharmaceutical company developing therapeutic solutions for neurodegenerative diseases is pleased to announce the company will present virtually at the 14th Annual European Life Sciences CEO Forum that will take place from  the 10th  to the 12th of March 2021, aspart of the Digital Sachs Spring Life Sciences Week.

Philippe Verwaerde, Chief Executive Officer of Alzprotect will provide an overview of the development program of the company’s drug Ezeprogind® and will be available for questions and one-on-one meetings with attendees registered for the conference.

Dr Verwaerde will also participate in a “Progress in Alzheimer’s Dementia and Diagnostic” panel on March 11th at 5 PM.

 “There is currently no available treatment to slow down or stop diseases related to neurodegeneration which affect tens of millions of people worldwide. Participating in this event allows us to share our unique innovation and progress involving the regulation of complex intracellular processes including inflammatory pathways and neuronal survival. Along with our experts, partners, and investors, we are proud of our recent progress and look forward to the next steps” Dr. Verwaerde said.

The 14th Annual ELSF is will include the BioCapital & Investment Day and the Bio-Pharma Partnering & Therapeutics Day on 10th and 11th of March. These two days will feature more than 14 hours of high-level speeches, panel discussions and spotlight showcases by more than 400 leading industry corporates.

Lille (France), November 23rd, 2020 – Alzprotect, a biopharmaceutical company developing therapeutic solutions for neurodegenerative diseases announces today that the United States Patent and Trademark Office (USPTO) has recently granted patent number US 10,772,884 concerning the therapeutic uses of its first-in-class clinical stage drug Ezeprogind (AZP2006) in the treatment of tauopathies. This patent completes the Ezeprogind related patents granted in the USA for composition of matter (US 9,562,018) and therapeutic uses in the treatment of Alzheimer’s and Parkinson’s diseases (US 10,537,569).

This strengthens Alzprotect portfolio of patents covering Ezeprogind that were already granted in Europe (EP 2 938 597 - validated in 26 member states of the European Patent Convention), and in 11 other countries including Japan (JP 6384923) and China (CN 105008333).

All these patents will be in force until at least 27th December 2033, subject to patent term adjustment or extension, and similar applications are currently under examination in Canada and Brazil.

Alzprotect co-owns or has an exclusive worldwide license from the French National Institute of Health and Medical research (Inserm) and the University of Lille (France) on a total of 58 patents related to Ezeprogind in 39 countries.

Alzprotect continues to expand the Ezeprogind intellectual property with the filing of two new European priority patent applications that will be extended to several other countries outside Europe directed to novel therapeutic uses for specific neurodegenerative diseases as well as new forms of the molecule intended for solid formulations of the drug.

Philippe Verwaerde, Chairman & Chief Executive Officer of Alzprotect, declared: “This new granted patent will reinforce our strong intellectual property portfolio which is a major asset for our company. I am also happy to extend it with two new applications in both therapeutic and formulation fields.

Cyrille Brantis, Intellectual Property Manager of Alzprotect, declared: “The grant of Ezeprogind composition of matter and therapeutic use patents in several major countries worldwide provides a significant protection of Ezeprogind’s intellectual property and is a key milestone for Alzprotect. The new patent applications are the outcome of years of high-quality research engaged by Alzprotect and highlight the company’s commitment to the development Ezeprogind.”  

Alzprotect is financed by the XERYS fund (Paris).

Interview Biotech Finances  25/06/2020